Table 2.
Clinical data of five Greek patients with MuSK-MG before and after immunosuppressive treatment.
| Patient code | Sex | Age at diagnosis | Duration of treatment (months) | Treatment status | MuSK Ab concentration (nM, cutoff for positivity: >0.030) | Time treatment started after onset | QMG | Treatment (immunosuppression, IS) |
|---|---|---|---|---|---|---|---|---|
| G1 | M | 79 | 54 months | Before | 27 | 0.6 months (20 days) | 4 | No IS |
| After | 21 | 0 | Prednisone | |||||
| G2 | F | 17 | 60 months | Before | 11 | 2 months | 2 | No IS |
| After | 5.5 | 0 | Prednisone | |||||
| G3 | F | 45 | 6 months | Before | 0.045 | 1 month | 3 | No IS |
| After | 0.1 | 1 | Prednisone | |||||
| G4 | F | 47 | 39 months | Before | n.a. | 6 months | 8 | No IS |
| After | 1.8 | 4 | Prednisone/Cyclosporine | |||||
| G5 | F | 49 | 33 months | Before | 13 | 3 months | 9 | No IS |
| After | 4.5 | 3 | Prednisone/Mycophenolate mofetil |
IS, immunosuppression.